Aitiologic Raises €6.4M Seed

Aitiologic, a precision medicine company headquartered in Vienna, has closed an oversubscribed €6.4 million seed financing round. The company specializes in tissue-resolved liquid biopsy solutions, using its proprietary Aitios platform to analyze cell-free DNA for medical diagnostic applications.

Investors

This financing round was co-led by Heal Capital and Ananda Impact Ventures. Additional investors participating in the round include PUSH VC, LANA Ventures, and Dr. Gordon Sanghera.

Aitiologic Use of Funds

Capital from this round will be used to support ongoing large-scale validation studies for the Aitios platform and to further the clinical development of the company's lead program, which focuses on first-trimester preeclampsia risk stratification.

About Aitiologic

Founded by Dr. Andreas E. Posch, Aitiologic is a precision medicine company that builds tissue-resolved liquid biopsy solutions. Its Aitios platform combines genomic, epigenomic, and fragmentomic data with AI interpretation to characterize biological changes from a routine blood draw, with an initial focus on maternal-fetal health.

Funding Details

Company Website: https://aitiologic.com

Company: Aitiologic
Raised: €6.4M
Round: Seed
Funding Date: September 15, 2026
Lead Investor: Heal Capital, Ananda Impact Ventures
Additional Investors: PUSH VC, LANA Ventures, Gordon Sanghera
Software Category: Precision Medicine
Source: https://www.biospace.com/press-releases/aitiologic-raises-6-4-million-in-oversubscribed-seed-financing-to-advance-tissue-resolved-liquid-biopsy-platform-and-preeclampsia-lead-program